Graphic B (IMAGE) The University of Hong Kong Caption Anti-angiogenic therapy suppresses choroidal neovascularisation (CNV) by inhibiting vascular endothelial growth factor (VEGF)-related pathways. The study represents the first attempt at integrating a photoactivatable anti-angiogenic agent with a photosensitiser into a single nanoformulation for age-related macular degeneration treatment, which opens up new avenues for the development of minimally-invasive therapeutics for AMD and other neovascular ocular disorders. Credit The University of Hong Kong Usage Restrictions N/A License Original content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.